Field Medical Secures $35 Million Series B Financing to Advance FieldForce™ PFA System for Ventricular Tachycardia Ablation

Heart Future

July 1, 2025, Innovative Company in the Field of Pulsed Field AblationField MedicalAnnouncement Completed$35 million(approximatelyRMB 250 million) of the Series B financing.

# Financing Details

Field Medical was founded in 2022 by“PFA"Father of"Steven MickelsenFounded, focusing on developing atrial fibrillation treatment solutions based on Pulsed Field Ablation (PFA) technology.

Its core productFieldForce™Ablation SystemAiming to initiate ventricular tachycardia through penetrative lesions (VT) Ablation therapy.

This round of financing was led byBioStar Capital and Cue Growth jointly led the investment, with existing strategic investors also participating.ThisFunds willUsed to advanceFieldForce™The development of the system, and support for the upcomingVERITAS Pivotal Clinical Trial。

VERITAS Clinical TrialIs a key clinical study aimed at advancing its next-generation PFA technology in the treatment of complex arrhythmias, particularly VT. The trial is conducted by Field Medical to validate its FieldForce™.SystemThe pivotal trial designed to evaluate safety and efficacy marks an important step for the company as it advances into the crucial clinical stage.

Just this yearOn April 21, Field Medical announced the successful completion of$40 millionof the Series A round. To date, the company's total financing amount has reached$75 million（ApproximatelyRMB540 million）。

As the company advances to the next stage of its development plan，Field Medical also adjusted the composition of its board members.The new board members include several individuals from the medical technology and venture capital sectors, including Marlou Janssen, former president of Biotronik USA, and EnterMark Wisniewski, Chief Financial Officer of ra Medical, and Ben Cannon, Founding Partner of Cue Growth, etc.

# HighTubeEvaluation

Founder and CEO of Field Medical, Father of PFASteven Mickelsen"VT is one of the least penetrated segments in electrophysiology, and physicians still lack the necessary tools for treatment. Excitingly, the trajectory of the VT market resembles the early stages of the atrial fibrillation market — strong clinical demand but existing technologies fall short. We are seizing this opportunity with next-generation therapies that deliver speed, precision, and true clinical advancements, redefining the possibilities of VT treatment for high-risk patients."

Founder and Senior Managing Partner of BioStar CapitalLouis CannonSaid: "Field Medical’s disruptive technology is doing what few companies dare to venture into — addressing one of the most difficult and overlooked challenges in cardiology with true innovation and urgency. Their physician-led team has unique insights, and the FieldForce platform provides the right tools. We are extremely proud to support them as they move into the next phase of transforming VT treatment."

CFO of Field MedicalOskar Dadason"This round of financing reflects the growing momentum of Field Medical, not only in our clinical outcomes but also in our solid commercial foundation. Our outstanding performance at the HRS conference attracted institutional investors and reinforced the continued support of existing investors, fully demonstrating the external confidence in our technology, strategy, and leadership."

• FieldForce CatheterTip AdoptionFieldBending Technology, A unique built-in electrode is placed in the fluid lumen as shown in the cross-sectional view., by transmitting voltage between the external and internal electrodes, the desired electric field characteristics are generated.
  
• Patient tolerance to PFA is a fundamental challenge, as remote stimulation may cause discomfort or involuntary movements. FieldBending features electrodes within the catheter's saline flush lumen, with a non-conductive tip at the distal end and an external electrode. The current flows from a 3mm outer ring located 4mm from the distal tip to the internal electrode.ThisNewBipolar Pulse Electrode Configuration, which can significantly improve the tolerance of PFA.。
• The contact force between the catheter and tissue plays an important role in the efficacy of PFA treatment.Increasing contact force can expand treatment depth., and requires electrode-tissue contact to effectively intervene in the lesion area.

▲Steven Mickelsen

Dr. Steven MickelsenIs a board-certified clinical cardiac electrophysiologist and an experienced business leader. In the cardiac care industry, he is a pioneer in introducing pulsed field ablation technology for patient treatment and is acclaimed as"Father of PFA"。

Dr. MickelsenFirst established FARAPULSE, the company isThe Developer of the 1st Generation PFA Technology。FARAPULSE Finally Acquired by Boston ScientificDr. Mickelsen's work in the PFA field has laid the foundation for the development and clinical application of this technology.

Subsequently,Dr. Mickelsen in 2022Founded Field Medical, the company focuses onDevelopment of Improved PFA Technology, such as FieldForce catheters and FieldForce generators, and introduced the patented FieldBending technology, which significantlyAuthorImproved the efficacy and safety of PFA in treating arrhythmias, especially complex ventricular arrhythmias.。

SiYu Annual Activity Review:The First Global Ophthalmology Conference | The First Global Orthopedics Conference | The First Global Cardiovascular Conference| The First Global Medical Aesthetics Technology Conference

Coming Soon:

July 17, 2025, The 2nd Global Medical Technology Conference

September 3-5, 2025, The 3rd Global Surgical Robotics Conference